SAB Biotherapeutics

SAB Biotherapeutics announces new CEO

Sioux Falls-based SAB Biotherapeutics Inc. has a new CEO.

1 month ago

Movers & Shakers

Here’s a look at this week’s Movers & Shakers.

4 months ago

SAB Biotherapeutics announces up to $130M in funding for diabetes treatment

Sioux Falls-based SAB Biotherapeutics has secured a private placement offering that will provide up to $130 million to advance development of its new treatment for Type 1 diabetes.

6 months ago

FDA grants fast track designation to SAB’s influenza therapeutic

The U.S. Food and Drug Administration has cleared Sioux Falls-based SAB Biotherapeutics to move ahead with “fast track designation” for its therapeutic showing promising results in treating influenza.

12 months ago

Pharmaceutical leader with global reach joins SAB Biotherapeutics as chief medical officer

She led efforts to bring drugs to market at Pfizer Inc. and Sanofi. Now, she’s helping bring a Sioux Falls biotech company’s therapeutics to patients.

12 months ago

CEO Series: Eddie Sullivan

From going public to navigating the pandemic, we sat down with SAB Biotherapeutics CEO Eddie Sullivan for our latest CEO Series.

1 year ago

SAB releases year-end earnings, company update

Sioux Falls-based SAB Biotherapeutics provided updates on its therapeutics for COVID-19, influenza and type 1 diabetes in reporting its year-end earnings last week.

2 years ago

SAB: COVID-19 therapeutic neutralized Omicron variant

The COVID-19 antibody treatment developed by Sioux Falls-based SAB Biotherapeutics has neutralized the Omicron variant in FDA laboratory testing, the company reported.

2 years ago

SAB reports progress with treatment for influenza

SAB Biotherapeutics is reporting promising news around its new treatment for the influenza virus.

2 years ago

SAB Biotherapeutics files first earnings report

Sioux Falls-based SAB Biotherapeutics has released its first earnings report since becoming a publicly traded company.

2 years ago

News Tip

Have a business news item to share with us?

Scroll to top